Press release
Tuberculosis Pipeline Analysis of 35+ Companies by Delveinsight
Tuberculosis Pipeline
Tuberculosis: An Overview
Tuberculosis (TB) is a bacterial infection spread through inhaling tiny droplets from the coughs or sneezes of an infected person. Tuberculosis (TB) is caused by a bacterium called Mycobacterium tuberculosis. The bacteria usually attack the lungs, but TB bacteria can attack any part of the body such as the kidney, spine, and brain. Not everyone infected with TB bacteria becomes sick. As a result, two TB-related conditions exist: latent TB infection (LTBI) and TB disease.
Request for sample and discover more about the Tuberculosis report offerings- https://www.delveinsight.com/sample-request/tuberculosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Regions Covered in the Report
• Global
The Tuberculosis Pipeline Report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Tuberculosis products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Tuberculosis pipeline landscape.
Tuberculosis Stages
Tuberculosis (TB) is a chronic, progressive mycobacterial infection, often with a period of latency following initial infection. Tuberculosis may occur in 3 stages:
• Primary infection- M. Tuberculosis bacilli initially cause a primary infection, which uncommonly causes acute illness.
• Latent infection- Most (about 95%) primary infections are asymptomatic and followed by a latent (dormant) phase.
• Active infection- A variable percentage of latent infections subsequently reactivate with symptoms and signs of disease.
Tuberculosis Treatment
Tuberculosis is a treatable and curable disease. Active, drug-susceptible TB disease is treated with a standard 6-month course of 4 antimicrobial drugs that are provided with information and support to the patient by a health worker or trained volunteer. The most common medications used to treat tuberculosis include: Rifampin, Isoniazid, Pyrazinamide and Ethambutol.
Find a snapshot of the Tuberculosis Pipeline Report- https://www.delveinsight.com/sample-request/tuberculosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Tuberculosis Therapeutics Assessment
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Therapeutics Assessment By Route of Administration: Oral, Parenteral, Subcutaneous, Topical, Intravenous
• Therapeutics Assessment By Molecule Type: Gene therapy, Small molecule, Polymers, Peptides, Monoclonal antibodies
• Therapeutics Assessment By Mechanism of Action: Bacterial growth inhibitors, Electron transport complex III inhibitors, Leukotriene inhibitors, Immunostimulants, Adenosine triphosphatase inhibitors, DprE1 protein inhibitors, Interferon type I stimulants; T lymphocyte stimulants.
Tuberculosis Causes
Tuberculosis is caused by bacteria that spread from person to person through microscopic droplets released into the air. This can happen when someone with the untreated, active form of Tuberculosis coughs, speaks, sneezes, spits, laughs or sings. Although Tuberculosis is contagious, it's not easy to catch. Most people with active TB who've had appropriate drug treatment for at least two weeks are no longer contagious.
Tuberculosis Emerging Drugs
Telacebec (Q203): Qurient Co
Telacebec (Q203) is one of the first candidates getting close to forming new universal regimen. Telacebec (Q203) is an orally active small molecule drug candidate that blocks Mycobacterium tuberculosis growth by inhibiting cytochrome bc1 complex, leading to the depletion of adenosine triphosphate (ATP) synthesis of M. tuberculosis. Telacebec (Q203) shows good synergy with bedaquiline in murine chronic infection model, indicating promising potential for new drug regimen. The drug is currently in phase 2 stage of development.
VPM1002: Serum Institute of India
VPM1002 facilitates mycobacterial antigens being released into the cytosol while also triggering autophagy, inflammasome activation, and apoptosis, because of antigens and bacterial DNA being released into the cytosol of the host cell due to Listeriolysin O expression in this vaccine. Mycobacterial antigen accessing the cytosol also improves antigen presentation. The ability for mycobacterial antigens to reach the cytosol is due to this vaccine being engineered to secrete Hly which perforates phagosomal membranes. Currently, it is in phase III stage of development for the treatment of Tuberculosis.
Tuberculosis Phases
DelveInsight's report covers around 35+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Learn more about Tuberculosis Drugs Pipeline- https://www.delveinsight.com/report-store/tuberculosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Tuberculosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Telacebec (Q203): Qurient Co
8. Mid Stage Products (Phase II)
9. WX-081: Shanghai Jiatan Pharmatech
10. Early Stage Products (Phase I/II)
11. OPC-167832: Otsuka Pharmaceutical
12. Inactive Products
13. Tuberculosis Key Companies
14. Tuberculosis Key Products
15. Tuberculosis Unmet Needs
16. Tuberculosis Market Drivers and Barriers
17. Tuberculosis Future Perspectives and Conclusion
18. Tuberculosis Analyst Views
19. Tuberculosis Key Companies
20. Appendix
Get in touch with our Business Consultant- https://www.delveinsight.com/report-store/tuberculosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Other Trending Reports:
• Aesthetic Implants Market: https://www.delveinsight.com/report-store/aesthetic-implants-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
• Onycholysis Market: https://www.delveinsight.com/report-store/onycholysis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
• France Healthcare Outlook Report: https://www.delveinsight.com/report-store/france-healthcare-outlook-report?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
• Italy Healthcare Outlook Report: https://www.delveinsight.com/report-store/italy-healthcare-outlook-report?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
• Primary Progressive Multiple Sclerosis Ppms Market: https://www.delveinsight.com/report-store/primary-progressive-multiple-sclerosis-ppms-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Contact Info:
Yashveer Bhardwaj
Email: info@delveinsight.com
https://www.delveinsight.com/
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Tuberculosis Pipeline Analysis of 35+ Companies by Delveinsight here
News-ID: 2681276 • Views: …
More Releases from DelveInsight Business Research
Spasticity Clinical Pipeline 2025: A Comprehensive Review of 12+ Emerging Therap …
According to DelveInsight's latest analysis, the global Spasticity pipeline features more than 10 active pharmaceutical companies that are advancing over 12 investigational therapies. The report offers a detailed evaluation of clinical trials, mechanisms of action, therapeutic approaches, routes of administration, and major developmental activities shaping the Spasticity treatment landscape.
DelveInsight's report, "Spasticity Pipeline Insight, 2025," delivers an extensive overview of the current clinical development environment and the future outlook for the…
Real-World Evidence Solution Market is set to grow at a 8.07% CAGR, reaching USD …
According to DelveInsight, the real-world evidence (RWE) solutions market is expanding rapidly, primarily due to the increasing global burden of chronic diseases and the growing need to improve healthcare outcomes. In addition, advancements in big data analytics, artificial intelligence, and machine learning are enhancing the ability to efficiently process and interpret large-scale real-world datasets. The rising adoption of RWE solutions by pharmaceutical and biotechnology companies - to support drug development,…
Spinal Implants Market is set to grow at a 5.50% CAGR, reaching USD 21.9 billion …
According to DelveInsight's assessment, the rising burden of spinal disorders particularly within the growing elderly population - continues to significantly increase the demand for surgical correction procedures. Alongside this, the surge in sports-related injuries and trauma cases is accelerating the need for advanced implantable spinal solutions. There is also a notable shift toward non-fusion and motion-preserving devices that support spinal flexibility and enhance patient outcomes, especially for younger and more…
Vascular Stents Market is set to grow at a 6.65% CAGR, reaching USD 18.28 billio …
According to DelveInsight's assessment, the rising global burden of cancer is significantly increasing the demand for advanced treatment approaches such as tumor ablation. Minimally invasive ablation techniques are gaining strong traction due to their advantages, including faster recovery times, lower complication risks, and reduced costs compared with traditional surgical procedures. At the same time, continuous improvements in ablation technologies - particularly in radiofrequency, microwave, and cryoablation systems - have enhanced…
More Releases for Tuberculosis
Revolutionizing the Fight Against Tuberculosis: Global Anti-Tuberculosis Therape …
The global Anti-Tuberculosis (TB) Therapeutics Market is on the cusp of a transformative era, driven by urgent medical need, groundbreaking scientific advances, and expanding public-private partnerships. With an estimated 10 million new TB cases reported worldwide in 2022 and 1.4 million deaths, tuberculosis remains a leading infectious disease killer, commanding critical attention from healthcare providers, governments, and pharmaceutical innovators alike. As the world rallies to eliminate this centuries-old scourge, the…
Latent Tuberculosis Infection Detection Market
Latent Tuberculosis Infection Detection Market worth $2.37 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Latent Tuberculosis Infection Detection Market - (By Brand (QFT-Plus), By Test Type (Tuberculin Skin Test (TST), Interferon Gamma Release Assay (IGRA)), By Application, By End-use), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research…
Tuberculosis (TB) Diagnostics Market - Detect, Diagnose, Defeat: Innovating Solu …
Newark, New Castle, USA - new report, titled Tuberculosis (TB) Diagnostics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Tuberculosis (TB) Diagnostics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Tuberculosis (TB) Diagnostics market. The report offers an overview of…
Conquering Tuberculosis: Exploring the Innovations in Mycobacterium Tuberculosis …
The global mycobacterium tuberculosis treatment market was valued at US$ 1.97 Bn in 2021 and is expected to increase at a CAGR of 1.2% over the forecast period 2022-2032.
Mycobacterium tuberculosis is a bacteria that causes tuberculosis (TB), which mostly affects the lungs. Tuberculosis is a major public health crisis concern; however, it can be cured and prevented. Adults are most often affected by tuberculosis during their most productive years. Over…
World Tuberculosis Day - Tuberculosis, the invisible pandemic
Tuberculosis is a disease that, every year, kills as many as COVID-19 does.
March 24, World Tuberculosis Day, marks the anniversary of a momentous occasion - the discovery of the bacterium which causes tuberculosis in 1882. More than a hundred years after its discovery, tuberculosis is still a global health crisis. It is the leading cause of death from a single infectious disease agent, killing close to as many people per…
Ocular Tuberculosis Therapeutics Market To Expand On Account Of Rising Tuberculo …
Research Nester released a report titled “Ocular Tuberculosis Therapeutics Market: Global Demand Analysis & Opportunity Outlook 2027” which delivers detailed overview of the global ocular tuberculosis therapeutics market in terms of market segmentation by treatment, by end user and by region.
Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.
Ocular tuberculosis is a type…
